Shionogi Announces Planned $2 Billion IntraBio Acquisition

The Reuters wire explicitly states that Shionogi plans to acquire all outstanding shares of IntraBio for USD 2.0 billion in upfront consideration, making this a material, forward-looking M&A development rather than market commentary. The transaction expands Shionogi’s rare-disease business, but it has not been completed and its effect on fiscal-year 2027 consolidated results remains under review. The occurrence time is estimated from the contemporaneous wire timestamp; the acquirer and Zevra, whose NPC product directly competes with IntraBio’s AQNEURSA, are approved stakeholders, while more indirect competitors, payers, distributors, and service providers are excluded as speculative.